(Q37585663)

21 August 2017

1 reference

title

Diabetic neuropathy: therapies on the horizon (English)

1 reference

21 August 2017

1 reference

Danish Mahmood

1

1 reference

21 August 2017

Bhulan Kumar Singh

series ordinal

2

1 reference

21 August 2017

Mohammad Akhtar

series ordinal

3

1 reference

21 August 2017

publication date

1 September 2009

1 reference

Journal of Pharmacy and Pharmacology

21 August 2017

published in

1 reference

21 August 2017

volume

61

1 reference

21 August 2017

issue

9

1 reference

21 August 2017

page(s)

1137-1145

1 reference

Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

The health care costs of diabetic peripheral neuropathy in the US.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Classification, differential diagnosis, and staging of diabetic peripheral neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Diabetic neuropathies: a statement by the American Diabetes Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Advanced glycation endproducts--role in pathology of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Role of advanced glycation end products and their receptors in development of diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Protein kinase C activation and its pharmacological inhibition in vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Sonic hedgehog induces arteriogenesis in diabetic vasa nervorum and restores function in diabetic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Nonviral gene transfer of human hepatocyte growth factor improves streptozotocin-induced diabetic neuropathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Depletion of substance P and calcitonin gene-related peptide in sciatic nerve of rats with experimental diabetes; effects of insulin and aldose reductase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Growth factors as therapeutics for diabetic neuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Diabetic neuropathy: pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Aldose reductase in diabetic microvascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Ranirestat (AS-3201), a potent aldose reductase inhibitor, reduces sorbitol levels and improves motor nerve conduction velocity in streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Aldose reductase, still a compelling target for diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

The therapeutic potential of poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraep

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

FK1706, a novel non-immunosuppressive immunophilin ligand, modifies the course of painful diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Protein kinase C activation and the development of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Effects of the protein kinase C beta inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Taurine counteracts oxidative stress and nerve growth factor deficit in early experimental diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Preventive effect of acetyl-L-carnitine on the thermal hypoalgesia in streptozotocin-induced diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Lycopene attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Molecular aspects of lipoic acid in the prevention of diabetes complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

The diabetic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Effect of resveratrol, a polyphenolic phytoalexin, on thermal hyperalgesia in a mouse model of diabetic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

A lipoic acid-gamma linolenic acid conjugate is effective against multiple indices of experimental diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

The effect of gamma-linolenic acid-alpha-lipoic acid on functional deficits in the peripheral and central nervous system of streptozotocin-diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Alpha-lipoic acid supplementation and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Erythropoietin for neurologic protection and diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Effects of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.61.09.0002

21 January 2018

Identifiers

DOI

10.1211/JPP.61.09.0002

1 reference

21 August 2017

1 reference